Trump Administration Strikes Major Deal with Pharma Giants: Ozempic Prices Slashed!
In an unprecedented move, President Trump has announced a landmark deal with Novo Nordisk and Eli Lilly to significantly reduce the prices of popular GLP-1 medications, including Ozempic and Wegovy. These drugs, crucial for diabetes and obesity treatment, will see slashed prices for Medicare, Medicaid, and cash-paying patients, all part of the new TrumpRx initiative aimed at broadening access and alleviating drug costs. The deal reflects a pivotal shift in U.S. healthcare policy with far-reaching implications for patients and the pharmaceutical industry.
Nov 15